MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Medtronic Stent's Safety Claims Take a Hit

Medtronic has been trying to get regulators and clinicians to believe that its drug-eluting stent, Endeavor, should be approved and used over existing products because it is safer. However, clinical data revealed Friday throw a wrench into the claim, Bloomberg News reports. Those data show Endeavor to be more associated with blood clots than Boston Scientific's Taxus.

(However, this did not translate into deaths and heart attacks, which were lower for Endeavor patients than Taxus ones.) This is not the best time for such news. Endeavor will be discussed by an FDA advisory panel on Wednesday, after which the panel will decide whether to recommend it for approval. Even if Endeavor does get through FDA, the new data gives Boston Scientific marketing ammunition.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.